Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pathophysiol. Nov 15, 2014; 5(4): 450-456
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.450
Table 2 Types of biomarkers in Barrett’s esophagus
DiagnosticTFF3IHCTo screen asymptomatic patients for BE[49,50]
Chromosome 7 and 17 changesIDKA and FISHEarly stages of BE[52]
8q24 (C-MYC), 17q12 (HER2), and 20q13 changesFISHEarly stages of BE[53]
17q11.2 (ERBB2)Microarray analysisEAC[54]
Serum proteomic analysisMass spectrometryEAC[55]
PredictiveP16 allelic lossFISHResponse to therapy[56]
DNA ploidy abnormalitiesICDACovariate value for recurrence[57]
HSP27IHCNo response to therapy[58]
Ephrin B receptorMicroarrayResponse to therapy in EAC[59]
Genetic polymorphismqRT-PCRAssociated with clinical outcome[60]
P21IHCCorrelated with better CTX response[61]
P53IHCCorrelated with better CTX response[62]
Progression markersERCC1IHCPredicts CTX resistance[16]
P53IHCLimited efficacy as a progression marker[13,63]
DNA abnormalitiesFlow cytometryHigh risk for progression to EAC[13]
LOH of 157p and 9pFlow cytometryPredict progression to EAC[14]
EGFRIHCOverexpression in HGD and EAC[64]
Cyclin AIHCPredicts progression to dysplasia[65]
Cyclin D1IHCRisk of Progression to EAC[19]
Hypermethylation of p16, RUNX2,HPP1RT-PCRRisk of progression to EAC/HGD[22]
8 gene methylation panelRT-PCRPredicts progression to EAC/HGD[66]
Prognostic biomarkersCathepsin D,AKR1D10,AKR1C2 mRNA levelsWestern blot, qRt-PCRDysregulation predicts progression to EAC/HGD[67]
DCK, PAPSS2, SIRT,TRIM44RT-PCR, IHC4 gene signature in EAC , predict 5 year survival[56]
P16 loss, C-MYC gainFISHAssociated with therapy response[68]
ASS expressionMicroarrayLow expression associated with metastases[69]
MicroRNA expression profileMicroarray, RT-PCRLow level associated with worse prognosis in EAC[70]
Cyclin D1IHC, FISHDecreased survival[71]
EGFRIHCDecreased expression associated with decreased survival[72]
TGF-αIHC, ISHHigh level indicates progression and metastases[73]
TGF-β1RT-PCR, ELISAHigh expression associated with decreased survival[73]
APCPCRHigh level associated with decreased survival[74]
COX-2IHCAssociated with metastases and recurrence[75]
TelomeraseSouthern-blot and PCRAssociated with decreased survival[76]
VEGFIHCAssociated with metastases and decreased survival[77]
CadherinIHCDecreased level associated with decreased survival[78]
TIMPIHC, PCRDecreased level associated with decreased survival[79]